The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease.
INFLAMMATORY BOWEL DISEASE
INTESTINAL MICROBIOLOGY
ULCERATIVE COLITIS
Journal
Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
27
03
2023
accepted:
16
05
2023
medline:
9
8
2023
pubmed:
21
6
2023
entrez:
20
6
2023
Statut:
ppublish
Résumé
Several randomised clinical trials (RCTs) performing faecal microbiota transplantation (FMT) for the management of inflammatory bowel disease (IBD), particularly for ulcerative colitis, have recently been published, but with major variations in study design. These include differences in administered dose, route and frequency of delivery, type of placebo and evaluated endpoints. Although the overall outcomes appear to be promising, they are highly dependent on both donor and recipient factors. To develop concensus-based statements and recommendations for the evaluation, management and potential treatment of IBD using FMT in order to move towards standardised practices. An international panel of experts convened several times to generate evidence-based guidelines by performing a deep evaluation of currently available and/or published data. Twenty-five experts in IBD, immunology and microbiology collaborated in different working groups to provide statements on the following key issues related to FMT in IBD: (A) pathogenesis and rationale, (B) donor selection and biobanking, (C) FMT practices and (D) consideration of future studies and perspectives. Statements were evaluated and voted on by all members using an electronic Delphi process, culminating in a plenary consensus conference and generation of proposed guidelines. Our group has provided specific statements and recommendations, based on best available evidence, with the end goal of providing guidance and general criteria required to promote FMT as a recognised strategy for the treatment of IBD.
Sections du résumé
BACKGROUND
Several randomised clinical trials (RCTs) performing faecal microbiota transplantation (FMT) for the management of inflammatory bowel disease (IBD), particularly for ulcerative colitis, have recently been published, but with major variations in study design. These include differences in administered dose, route and frequency of delivery, type of placebo and evaluated endpoints. Although the overall outcomes appear to be promising, they are highly dependent on both donor and recipient factors.
OBJECTIVE
To develop concensus-based statements and recommendations for the evaluation, management and potential treatment of IBD using FMT in order to move towards standardised practices.
DESIGN
An international panel of experts convened several times to generate evidence-based guidelines by performing a deep evaluation of currently available and/or published data. Twenty-five experts in IBD, immunology and microbiology collaborated in different working groups to provide statements on the following key issues related to FMT in IBD: (A) pathogenesis and rationale, (B) donor selection and biobanking, (C) FMT practices and (D) consideration of future studies and perspectives. Statements were evaluated and voted on by all members using an electronic Delphi process, culminating in a plenary consensus conference and generation of proposed guidelines.
RESULTS AND CONCLUSIONS
Our group has provided specific statements and recommendations, based on best available evidence, with the end goal of providing guidance and general criteria required to promote FMT as a recognised strategy for the treatment of IBD.
Identifiants
pubmed: 37339849
pii: gutjnl-2023-329948
doi: 10.1136/gutjnl-2023-329948
pmc: PMC10423477
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1642-1650Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Gut. 2017 Apr;66(4):569-580
pubmed: 28087657
J Crohns Colitis. 2017 Oct 01;11(10):1180-1199
pubmed: 28486648
Cell Host Microbe. 2022 Feb 9;30(2):183-199.e10
pubmed: 35085504
Aliment Pharmacol Ther. 2017 Sep;46(5):479-493
pubmed: 28707337
Pharmacol Ther. 2015 May;149:191-212
pubmed: 25561343
Gastroenterol Res Pract. 2019 Apr 15;2019:1287493
pubmed: 31178906
Am J Gastroenterol. 2013 Oct;108(10):1620-30
pubmed: 24060759
Inflamm Bowel Dis. 2020 Jun 18;26(7):1079-1086
pubmed: 31587035
Aliment Pharmacol Ther. 2017 Aug;46(3):213-224
pubmed: 28612983
Inflamm Bowel Dis. 2013 Sep;19(10):2155-65
pubmed: 23899544
Nat Genet. 2022 Feb;54(2):134-142
pubmed: 35115689
Gastroenterology. 2015 Jul;149(1):110-118.e4
pubmed: 25836986
J Crohns Colitis. 2022 Aug 30;16(8):1185-1186
pubmed: 35194635
JAMA. 2017 Nov 28;318(20):1985-1993
pubmed: 29183074
Lancet Gastroenterol Hepatol. 2022 Feb;7(2):141-151
pubmed: 34863330
Tech Coloproctol. 2021 May;25(5):495-504
pubmed: 33759066
J Clin Med. 2021 Jun 22;10(13):
pubmed: 34206663
Int J Colorectal Dis. 2016 May;31(5):1093-1094
pubmed: 26525055
Inflamm Intest Dis. 2019 May;4(1):1-6
pubmed: 31172007
Clin Microbiol Infect. 2014 Mar;20 Suppl 2:1-26
pubmed: 24118601
J Crohns Colitis. 2016 Apr;10(4):387-94
pubmed: 26519463
Nat Med. 2022 Sep;28(9):1913-1923
pubmed: 36109637
Am J Gastroenterol. 2013 Apr;108(4):500-8
pubmed: 23511459
Gut. 2018 Nov;67(11):1920-1941
pubmed: 30154172
J Crohns Colitis. 2022 Mar 14;16(3):369-378
pubmed: 34514495
Gut. 2020 Aug;69(8):1510-1519
pubmed: 32409589
Gut. 2021 Nov;70(11):2210-2211
pubmed: 33303563
Microbiome. 2020 Feb 3;8(1):12
pubmed: 32014035
Rev Esp Enferm Dig. 2022 Sep;114(9):543-549
pubmed: 35510325
Curr Opin Gastroenterol. 2015 Nov;31(6):456-63
pubmed: 26444824
Front Endocrinol (Lausanne). 2020 Jan 31;11:25
pubmed: 32082260
JAMA. 2016 Jan 12;315(2):142-9
pubmed: 26757463
Intest Res. 2018 Jan;16(1):142-146
pubmed: 29422809
Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16731-6
pubmed: 18936492
Dig Dis Sci. 2020 Apr;65(4):1099-1106
pubmed: 31302808
PLoS One. 2015 Aug 19;10(8):e0133925
pubmed: 26288277
Pathogens. 2022 Jul 21;11(7):
pubmed: 35890064
Nature. 2012 May 09;486(7402):222-7
pubmed: 22699611
Int J Colorectal Dis. 2020 Nov;35(11):2135-2136
pubmed: 32583041
Gastroenterology. 2011 May;140(6):1720-28
pubmed: 21530738
Cytokine. 2012 Sep;59(3):451-9
pubmed: 22795953
Cochrane Database Syst Rev. 2018 Nov 13;11:CD012774
pubmed: 30480772
Clin Infect Dis. 2018 Mar 19;66(7):e1-e48
pubmed: 29462280
J Hosp Infect. 2018 Sep;100 Suppl 1:S1-S31
pubmed: 30173851
Gut. 2022 Dec;71(12):2401-2413
pubmed: 35973787
Inflamm Bowel Dis. 2020 Aug 20;26(9):1415-1420
pubmed: 31821444
Sci Rep. 2015 Aug 12;5:12955
pubmed: 26264409
Gastroenterology. 2019 Jun;156(8):2174-2189
pubmed: 30880022
Gut. 2019 Dec;68(12):2111-2121
pubmed: 31563878
Ann Intern Med. 2016 Nov 01;165(9):609-616
pubmed: 27547925
Free Radic Biol Med. 2014 Mar;68:122-33
pubmed: 24275541
Inflamm Bowel Dis. 2017 Oct;23(10):1702-1709
pubmed: 28906291
Am J Gastroenterol. 2016 Mar;111(3):441-3
pubmed: 27018122
N Engl J Med. 2013 Jan 31;368(5):407-15
pubmed: 23323867
Nat Commun. 2018 Dec 5;9(1):5184
pubmed: 30518790
Gastroenterology. 2008 Feb;134(2):577-94
pubmed: 18242222
Aliment Pharmacol Ther. 2015 May;41(9):835-43
pubmed: 25728808
United European Gastroenterol J. 2018 Oct;6(8):1232-1244
pubmed: 30288286
N Engl J Med. 2019 Nov 21;381(21):2043-2050
pubmed: 31665575
Gastroenterology. 2015 Jul;149(1):102-109.e6
pubmed: 25857665
Int J Microbiol. 2019 Jul 01;2019:7395127
pubmed: 31354831
JAMA. 2019 Jan 15;321(2):156-164
pubmed: 30644982
Inflamm Bowel Dis. 2009 Mar;15(3):454-62
pubmed: 18831524
Lancet. 2017 Mar 25;389(10075):1218-1228
pubmed: 28214091